Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2025-04-25 Environmental & Social …
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司2024年环境、社会和公司治理（ESG）报告（英文）
Environmental & Social Information Classification · 100% confidence The document is titled as the 2024 Environmental, Social and Governance (ESG) Report of Aurisco Pharmaceutical Co., Ltd. It includes detailed sections on ESG governance, environmental management, social responsibility, corporate governance, and sustainability practices. The content covers the company's ESG practices, performance, governance structure, environmental initiatives, social contributions, and corporate culture. It references ESG reporting standards such as GRI Standards 2021, TCFD, and UN SDGs, and covers the full year 2024. The document is comprehensive and contains substantive non-financial data related to environmental, social, and governance factors. It is not a financial report like an annual or interim report, nor is it an announcement or certification. Therefore, it fits the category of Environmental & Social Information (ESG) report.
2025-04-25 Chinese
奥锐特药业股份有限公司2024年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled '2024 年度会计师事务所履职情况评估报告' which translates to '2024 Annual Evaluation Report on the Performance of the Accounting Firm'. It details the auditing firm Tianjian CPA's qualifications, risk management, litigation history, audit team, independence, audit fees, quality management, audit service plan, information security, and risk bearing capacity. The content focuses on the audit firm's performance and compliance related to the company's 2024 annual audit engagement. It does not contain the company's financial statements or management discussion and analysis, nor is it a full annual report or audit opinion report. Instead, it is an evaluation report on the auditor's performance and risk management, which fits the category of an Audit Report / Information (AR) as it relates to audit-related information but is not the full annual report itself. The document length is 3293 characters, which is relatively short but contains substantive audit-related information, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2024
2025-04-25 Chinese
奥锐特药业股份有限公司2024年度独立董事述职报告（陈应春）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2024 by an independent director of 奥锐特药业股份有限公司. It details the director's background, independence, attendance at meetings, communication with auditors, supervision of financial reporting and internal controls, and overall evaluation of their duties. The content focuses on the independent director's duties and oversight rather than financial results or audit opinions alone. It is a formal report on the director's activities and compliance with governance and regulatory requirements for the year. This type of document is typically classified under Board/Management Information (MANG) as it relates to governance and management oversight rather than a full annual report, audit report, or other financial filings. The document length is 3823 characters, which is substantial and contains detailed narrative rather than just an announcement or certification, so it is not RPA or RNS. Therefore, the best fit is MANG with high confidence.
2025-04-25 Chinese
奥锐特药业股份有限公司2025年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 First Quarter Report" of 奥锐特药业股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including balance sheet, income statement, and cash flow statement for the first quarter of 2025. The report includes unaudited financial data, key financial metrics, shareholder information, and management assurances about the accuracy of the report. The length of the document (over 11,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-25 Chinese
奥锐特药业股份有限公司关于召开2024年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2024 Annual General Meeting (AGM) of 奥锐特药业股份有限公司, including details about the meeting date, voting procedures, agenda items, and proxy forms. It does not contain the actual annual report or financial statements but rather informs shareholders about the upcoming AGM and the matters to be discussed and voted on, such as the 2024 annual report, board reports, financial reports, and remuneration plans. The document length is under 5,000 characters and primarily serves as a meeting notice and proxy solicitation. Therefore, it fits the category of AGM Information (AGM-R) rather than the full Annual Report (10-K) or Proxy Solicitation (PSI).
2025-04-25 Chinese
奥锐特药业股份有限公司非经营性资金占用及其他关联资金往来情况的专项审计说明
Audit Report / Information Classification · 95% confidence The document is an audit report specifically focused on the special audit of non-operating fund occupation and other related party fund transactions for the fiscal year 2024. It includes an auditor's opinion, references to auditing standards, and regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange. The document is titled as a special audit explanation and includes an audit conclusion. It is not a full annual report but a standalone audit report related to a specific aspect of the company's financials. The document length is short (1517 characters) but contains substantive audit content, not just an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2024
2025-04-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.